Basco L K, Le Bras J, Gillotin C, Ringwald P, Rabenjarson E, Gimenez F, Bouchaud O, Farinotti R, Coulaud J P
Department of Parasitology, Hôpital Bichat-Claude Bernard, Paris, France.
Trop Med Parasitol. 1991 Dec;42(4):413-4.
A case of recrudescent falciparum malaria after halofantrine treatment is described. The patient contracted Plasmodium falciparum in Ivory Coast and was treated with halofantrine. Plasma levels of halofantrine and its metabolite were adequate. Thirty-one days after treatment, the patient was rehospitalized with symptoms of malaria. Recrudescence was confirmed by microscopic examination, indicating a type RI resistance to halofantrine. Mefloquine was given to treat recrudescent malaria. The parasite was susceptible to chloroquine and quinine in vitro but displayed elevated values of 50% inhibitory concentration for mefloquine and halofantrine. The case reminds us that chloroquine still has an important therapeutic role against African strains of P. falciparum and that mefloquine and halofantrine should be reserved for multi drug-resistant P. falciparum.
本文描述了1例使用卤泛群治疗后复发的恶性疟病例。该患者在象牙海岸感染恶性疟原虫,接受卤泛群治疗。卤泛群及其代谢产物的血浆水平充足。治疗31天后,患者因疟疾症状再次住院。通过显微镜检查确诊为复发,表明对卤泛群存在RI型耐药。给予甲氟喹治疗复发的疟疾。该寄生虫在体外对氯喹和奎宁敏感,但对甲氟喹和卤泛群的50%抑制浓度值升高。该病例提醒我们,氯喹对非洲恶性疟原虫株仍具有重要的治疗作用,甲氟喹和卤泛群应保留用于多重耐药的恶性疟原虫。